NASDAQ · Financial Statements

Avalyn Pharma Inc. (AVLN) Revenue, Earnings & Financial Statements

$27.92 NASDAQ: AVLN Market Cap $1.24B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Avalyn Pharma Inc. most recently reported annual revenue of $0, a net loss of $85.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Income Statement — 1 Years (USD millions)

Metric2025
Revenue$0
Operating Expenses$91.0M
Operating Profit−$91.0M
Other Income$6.0M
Interest$0
Depreciation$0
Profit Before Tax−$85.0M
Tax rate (%)0.0%
Net Profit−$85.0M
EPS−$2.04

Quarterly Results — Last 5 Quarters (USD millions)

MetricMar '25Jun '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0
Operating Expenses$19.0M$22.0M$28.0M$31.0M$33.0M
Operating Profit−$19.0M−$22.0M−$28.0M−$31.0M−$33.0M
Interest$0$0$0$0$0
Profit Before Tax−$18.0M−$20.0M−$27.0M−$29.0M−$30.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%
Net Profit−$18.0M−$20.0M−$27.0M−$29.0M−$30.0M
EPS−$0.42−$0.48−$0.64−$0.65$0.00

Balance Sheet — 1 Years (USD millions)

Metric2025
Total Assets$149.0M
Current Assets$144.0M
Cash$52.0M
Inventory$0
Receivables$1.0M
Fixed Assets$2.0M
Capital Work in Progress$0
Investments$86.0M
Other Assets$0
Total Liabilities$388.0M
Current Liabilities$14.0M
Borrowings$2.0M
Other Liabilities$386.0M
Equity$0
Reserves−$239.0M

Cash Flow Statement — 1 Years (USD millions)

Metric2025
Operating Cash Flow−$81.0M
Investing Cash Flow$10.0M
Financing Cash Flow−$1.0M
Net Cash Flow$28.0M
Free Cash Flow−$82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.25
EV / EBITDA-19.95
FCF Yield-4.03%
Quick Ratio33.10
Interest Coverage-160.00
Return 1Y—
Return 3Y—
Return 5Y—

Avalyn Pharma Inc. (AVLN) financials — frequently asked questions

What is Avalyn Pharma Inc.'s annual revenue?

Avalyn Pharma Inc. (AVLN) reported annual revenue of $0 in its most recent fiscal year.

What is Avalyn Pharma Inc.'s net profit?

Avalyn Pharma Inc. (AVLN) reported a net loss of $85.0M in its most recent fiscal year.

What is AVLN EV/EBITDA?

Avalyn Pharma Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -19.95. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
AVLN Overview AVLN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.